All In Biotech

NDA 202450 · Azurity

Tudorza Pressair

Aclidinium Bromide · Inhalation

Novel

Last checked: Nov 20, 2026Latest source record: Mar 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Jul 23, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

42

21 Phase 3, 0 recruiting

FAERS reports

6,392

3,559 serious, 290 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 1, 2022.

TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). TUDORZA PRESSAIR is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (1)

Mechanism: Aclidinium bromide is a long-acting antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TUDORZA PRESSAIR · ACLIDINIUM BROMIDE 0.4MG/INH · POWDER, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aclidinium" as an intervention, any sponsor and status, largest first.

All 42 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,875
  • device malfunction1,282
  • drug dose omission1,017
  • asthma819
  • chronic obstructive pulmonary disease784
  • intentional product misuse741
  • off label use720
  • pneumonia718
  • wheezing666
  • cough658
  • product quality issue592
  • device issue475

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20092
20105
20116
201212
2013221
2014339
2015631
2016862
2017912
2018875
2019472
2020385
2021421
2022402
2023329
2024262
2025175
202681

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tudorza Pressair (Aclidinium Bromide)

2024 spending

$5.1M

Beneficiaries

1,936

7,487 claims

Per beneficiary

$2,614

$383.18 per unit

View as table
YearSpending
2020$25,612,948
2021$18,018,964
2022$14,437,296
2023$10,574,258
2024$5,059,840

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 79 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.